
    
      Double-masked, placebo-controlled, single-dose Phase 2 study in 24 patients experiencing
      severe night vision difficulties to evaluate ocular and systemic safety and efficacy
      following administration of one drop of phentolamine mesylate 1.0% QD in each eye for 1 day.
    
  